Clinical Trial Update: Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors [Phase 1]

View source ↗

Summary

Volitinib is being studied in a Phase 1 trial for patients with recurrent or refractory primary CNS tumors, with the study currently listed as active but not re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Neoplasm
• Diffuse Intrinsic Pontine Glioma
• Malignant Glioma
• Medulloblastoma

Drugs mentioned

• Volitinib (volitinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Malignant Glioma | Phase 1 | Status: ACTIVE_NOT_RECRUITING